A viral claim circulating online has reignited an uncomfortable question about modern medicine:
How can a cancer drug that costs hundreds or even thousands of dollars in one country be available for a fraction of that price somewhere else?
The image behind the claim suggests that an American woman discovered a commonly used cancer pill selling for around $900 in the United States and just $0.37 in India.
The exact figures should be treated cautiously. Drug prices vary enormously depending on the medication, dose, manufacturer, insurance coverage, pharmacy, and whether the product is a branded or generic version.
But the larger story behind the post is very real.
For several important cancer medicines, particularly older targeted drugs such as imatinib, patients in India can sometimes obtain generic versions for dramatically less than the prices associated with branded versions in the United States.
And the reasons reveal a great deal about patents, generic competition, pharmaceutical pricing, and how differently countries approach access to medicine.
The Cancer Drug That Changed Leukemia Treatment
One of the clearest examples is imatinib, originally marketed under the brand names Gleevec or Glivec.
Imatinib transformed the treatment of chronic myeloid leukemia, commonly known as CML.
Rather than functioning like traditional chemotherapy that broadly attacks rapidly dividing cells, imatinib is a targeted therapy. It blocks abnormal proteins involved in the growth of certain cancer cells.
It is also used for several other conditions, including some gastrointestinal stromal tumors.
For many patients with CML, medications such as imatinib turned a once extremely dangerous disease into a condition that can often be controlled for years.
But there was a problem.
The original branded medication became extraordinarily expensive in some markets.
Historical analyses have documented U.S. prices reaching tens of thousands—and eventually more than $100,000—per year for branded imatinib therapy.
Meanwhile, generic versions became available in India for a small fraction of those amounts.
Why Can the Same Active Ingredient Cost So Much Less?
The answer is more complicated than simply saying one country charges too much.
Several forces affect drug prices.
1. Patent protection can limit competition
When pharmaceutical companies develop new medications, patents can provide a temporary period during which competitors cannot sell equivalent copies.
The purpose is to reward innovation and help companies recover research and development costs.
However, limited competition can also allow prices to remain high.
Once meaningful generic competition begins, prices can fall dramatically.
2. India Built a Huge Generic Drug Industry
India has become one of the world’s major manufacturers of generic pharmaceuticals.
Indian companies manufacture inexpensive versions of many medicines once legal conditions allow them to do so.
Competition between multiple manufacturers can push prices downward.
That difference can become particularly striking with medications patients need continuously for months or years.
3. India Has Taken a Different Approach to Some Drug Patents
One of the most famous pharmaceutical patent disputes involved Novartis and imatinib.
The company sought patent protection in India for a particular form of imatinib mesylate.
Indian authorities rejected the application, and after years of litigation, India’s Supreme Court upheld the rejection in 2013.
The decision became internationally significant because it limited certain forms of additional patent protection where changes to an existing medicine did not satisfy India’s legal requirements for patentability.
Generic manufacturers therefore continued producing lower-cost versions of imatinib.
At the time, independent organizations reported enormous differences between branded Glivec and Indian generic alternatives.
The Price Difference Can Be Huge—but Don’t Trust Every Viral Number
This is where social media posts can become misleading.
A claim like:
“$900 in America versus $0.37 in India”
may create an enormous amount of engagement, but it leaves out critical details.
Which medication?
Which dose?
One pill or an entire treatment cycle?
Brand-name medication or generic?
Retail price or negotiated price?
Insurance price or cash price?
Hospital pharmacy or online pharmacy?
These details can completely change the comparison.
Recent pricing data illustrate just how complicated this is.
One 2025 review of chronic myeloid leukemia treatment costs reported Indian generic imatinib at approximately $420–$840 annually, depending on the manufacturer. The same review also showed that inexpensive generic imatinib can now be available in the United States through certain low-cost channels, while other cancer therapies remain extraordinarily expensive.
Current Indian pharmacy listings also show substantial differences between manufacturers and formulations rather than one universal price.
So the viral claim should not be interpreted as meaning that every $900 American cancer pill costs 37 cents in India.
But the underlying phenomenon—massive international differences in cancer drug prices—is absolutely real.
India Also Regulates Prices of Essential Medicines
Generic competition is only part of the story.
India also has a government drug-price-control system.
The country’s National Pharmaceutical Pricing Authority establishes ceiling prices for many essential medicines, including a number of cancer drugs.
As of March 2026, the Indian government reported active ceiling prices covering 131 anti-cancer drugs, with its pricing measures estimated to have reduced costs substantially compared with earlier regulated levels.
Imatinib itself has appeared under India’s regulated pricing framework.
These controls create a pharmaceutical environment very different from one in which manufacturers have considerably more freedom to establish launch prices.
Generic Does Not Mean “Fake”
Another misunderstanding frequently appears whenever inexpensive Indian drugs are discussed.
A properly approved generic medicine is not simply a weak imitation of the original drug.
Generic drugs generally contain the same active pharmaceutical ingredient and must meet applicable regulatory standards.
However, manufacturing quality still matters.
Patients should never assume that every tablet sold through an unknown website is legitimate merely because the product claims to be an Indian generic.
Counterfeit, improperly stored, or unregulated medicines exist around the world.
Cancer medication should always come through legitimate medical and pharmaceutical channels.
Why Cancer Drug Prices Matter So Much
For medications used briefly, price differences are frustrating.
For medications that must be taken for years, they can become life-changing.
Many targeted cancer treatments are taken daily.
That means even a relatively modest difference per tablet can translate into thousands of dollars per year.
When the gap becomes hundreds of dollars per dose, access can become a question of whether a patient can continue treatment at all.
This is one reason the imatinib story became so influential.
It demonstrated that once multiple manufacturers can compete, the production cost of some established targeted therapies may be far below the prices once charged for branded versions.
Are Cancer Medicines Always Cheaper in India?
No.
Newer medications—particularly patented targeted therapies, immunotherapies, cellular therapies, and biologic drugs—can still be extremely expensive in India.
And even what appears inexpensive from an American or European perspective may remain unaffordable for many Indian families.
Income levels matter.
A $100 monthly drug may look remarkably inexpensive compared with a $5,000 alternative, but it can still represent a substantial financial burden for a household earning only a few hundred dollars per month.
Affordability therefore cannot be measured by price alone.
It must be considered relative to income and healthcare coverage.
Why Doesn’t the United States Simply Use Indian Prices?
There is no single answer.
The American pharmaceutical market involves a complicated network of:
- manufacturers
- pharmacy benefit managers
- insurance companies
- pharmacies
- hospitals
- government programs
- patent protections
- rebates
- negotiated discounts
The number appearing as a drug’s “list price” may also be very different from what an insurer ultimately pays or what a patient pays out of pocket.
In recent years, the United States has taken additional steps toward negotiating or limiting prices for some medications.
Still, major differences between American and international pharmaceutical prices remain.
Could Americans Simply Buy Cancer Drugs From India?
Patients should not treat international drug purchasing as a casual online shopping decision.
Importation rules vary, and medications obtained through unverified websites may be counterfeit, contaminated, improperly stored, incorrectly dosed, or entirely different from what the packaging claims.
More importantly, cancer therapy requires careful medical supervision.
The correct dose depends on the disease, treatment response, laboratory results, drug interactions, and sometimes genetic characteristics of the cancer.
A lower price is valuable only when the medication is legitimate and used safely.
There’s a Bigger Question Behind the Viral Story
The most interesting part of this story is not whether one specific pill costs exactly 37 cents.
It is what the comparison reveals.
A medicine can involve the same molecule, treat the same disease, and be manufactured using established pharmaceutical processes—yet its price can vary dramatically depending on where a patient lives.
Sometimes the difference comes from production costs.
But often it reflects patents, regulation, competition, distribution systems, insurance structures, and government policy.
That is why discussions about drug affordability cannot be reduced to the cost of manufacturing a tablet.
Healthcare systems decide who negotiates, who pays, how much competition exists, and ultimately how much medicine costs the patient.
The Bottom Line
The dramatic “$900 versus $0.37” comparison circulating online cannot be treated as a reliable universal price comparison without knowing exactly which drug, dose, manufacturer, and source are being discussed.
But dismissing the entire story would miss the larger truth.
Some cancer medicines genuinely cost dramatically less in India than comparable branded therapies have historically cost in the United States.
Imatinib is one of the clearest examples.
Generic manufacturing, patent policy, competition, and government price regulation have helped make certain cancer treatments substantially more affordable in India.
And that raises a question worth discussing:
If an effective medicine can be manufactured and sold profitably for dramatically less somewhere else, how should wealthy countries balance pharmaceutical innovation with patients’ ability to afford lifesaving treatment?
That debate is much bigger than one viral post—and it isn’t going away.
